MediWound (NASDAQ:MDWD) Stock Passes Above 50-Day Moving Average - What's Next?

MediWound Ltd. (NASDAQ:MDWD - Get Free Report)'s stock price crossed above its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $16.88 and traded as high as $18.22. MediWound shares last traded at $18.03, with a volume of 39,218 shares.

Analyst Ratings Changes

A number of research analysts have commented on the stock. Craig Hallum started coverage on shares of MediWound in a research report on Friday, February 28th. They issued a "buy" rating and a $39.00 target price on the stock. StockNews.com upgraded shares of MediWound to a "sell" rating in a report on Friday, March 21st. Finally, HC Wainwright reiterated a "buy" rating and issued a $25.00 target price on shares of MediWound in a report on Thursday, March 20th.

MediWound Stock Performance

The company has a market capitalization of $195.95 million, a price-to-earnings ratio of -6.25 and a beta of 0.50. The firm has a 50-day simple moving average of $16.87 and a two-hundred day simple moving average of $17.46.

MediWound (NASDAQ:MDWD - Get Free Report) last announced its quarterly earnings data on Wednesday, March 19th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, beating analysts' consensus estimates of ($0.59) by $0.23. The firm had revenue of $5.84 million during the quarter, compared to analysts' expectations of $5.79 million. MediWound had a negative net margin of 142.29% and a negative return on equity of 82.17%. During the same quarter in the previous year, the business posted ($0.19) earnings per share. As a group, equities analysts forecast that MediWound Ltd. will post -2.66 EPS for the current fiscal year.

Institutional Investors Weigh In On MediWound

Hedge funds and other institutional investors have recently made changes to their positions in the business. Yelin Lapidot Holdings Management Ltd. grew its stake in MediWound by 0.8% during the 1st quarter. Yelin Lapidot Holdings Management Ltd. now owns 858,000 shares of the biopharmaceutical company's stock worth $13,316,000 after buying an additional 6,639 shares during the last quarter. Essex Investment Management Co. LLC grew its position in shares of MediWound by 30.7% during the fourth quarter. Essex Investment Management Co. LLC now owns 148,949 shares of the biopharmaceutical company's stock worth $2,651,000 after acquiring an additional 35,012 shares during the last quarter. Northern Trust Corp increased its holdings in shares of MediWound by 94.6% in the 4th quarter. Northern Trust Corp now owns 144,768 shares of the biopharmaceutical company's stock valued at $2,577,000 after acquiring an additional 70,367 shares during the period. Sargent Investment Group LLC increased its holdings in shares of MediWound by 3.4% in the 4th quarter. Sargent Investment Group LLC now owns 121,190 shares of the biopharmaceutical company's stock valued at $2,217,000 after acquiring an additional 3,998 shares during the period. Finally, Silverberg Bernstein Capital Management LLC raised its position in MediWound by 13.1% in the 1st quarter. Silverberg Bernstein Capital Management LLC now owns 103,944 shares of the biopharmaceutical company's stock valued at $1,613,000 after purchasing an additional 12,060 shares during the last quarter. Institutional investors and hedge funds own 46.83% of the company's stock.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.